AMY BETH HEIMBERGER

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients
    William Humphries
    Department of Neurosurgery, The University of Texas M, d, Anderson Cancer Center, Houston, TX, USA
    J Transl Med 7:92. 2009
  2. pmc The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients
    Amy B Heimberger
    University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Unit 422, Houston, TX 77230 1402, USA
    Expert Opin Biol Ther 9:1087-98. 2009
  3. doi request reprint Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas
    Amy B Heimberger
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:5166-72. 2008
  4. ncbi request reprint Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients
    Amy B Heimberger
    Department of Neurosurgery, University of Texas M D Anderson Cancer Center, Unit 442, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 11:1462-6. 2005
  5. pmc Mechanisms of action of rapamycin in gliomas
    Amy B Heimberger
    Brain Tumor Center, Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Neuro Oncol 7:1-11. 2005
  6. ncbi request reprint Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas
    Amy B Heimberger
    Department of Neurosurgery, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:267-72. 2005
  7. ncbi request reprint Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors
    Amy B Heimberger
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Unit 442, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 9:4247-54. 2003
  8. ncbi request reprint Biphasic malignant meningioma: a comparative genomic hybridization study
    A B Heimberger
    Department of Neurosurgery, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Neuropathol 21:258-64. 2002
  9. pmc Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?
    Amy B Heimberger
    Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Unit 442, FC7 3021, Houston, TX 77030 4009, USA
    Neuro Oncol 13:3-13. 2011
  10. pmc Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study
    Amy B Heimberger
    Department of Neurosurgery, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Neuro Oncol 10:98-103. 2008

Detail Information

Publications36

  1. pmc yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients
    William Humphries
    Department of Neurosurgery, The University of Texas M, d, Anderson Cancer Center, Houston, TX, USA
    J Transl Med 7:92. 2009
    ....
  2. pmc The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients
    Amy B Heimberger
    University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Unit 422, Houston, TX 77230 1402, USA
    Expert Opin Biol Ther 9:1087-98. 2009
    ..Further therapeutic strategies and potential pitfalls of using this approach are discussed...
  3. doi request reprint Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas
    Amy B Heimberger
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:5166-72. 2008
    ..Our hypothesis is that only the most malignant gliomas have a prominent glioma-infiltrating Treg population that contributes to the immunosuppressive biology and that the presence of Tregs is a negative prognostic variable...
  4. ncbi request reprint Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients
    Amy B Heimberger
    Department of Neurosurgery, University of Texas M D Anderson Cancer Center, Unit 442, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 11:1462-6. 2005
    ..We sought to determine whether glioblastoma multiforme expression of either overexpressed wild-type EGFR or the mutant EGFRvIII is an independent predictor of overall patient survival...
  5. pmc Mechanisms of action of rapamycin in gliomas
    Amy B Heimberger
    Brain Tumor Center, Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Neuro Oncol 7:1-11. 2005
    ....
  6. ncbi request reprint Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas
    Amy B Heimberger
    Department of Neurosurgery, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:267-72. 2005
    ..The purpose of our study was to determine AP-2alpha expression distribution among grades of gliomas and any possible effect on prognosis...
  7. ncbi request reprint Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors
    Amy B Heimberger
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Unit 442, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 9:4247-54. 2003
    ..In the study described here, we tested in mouse models a vaccine consisting of a peptide encompassing the tumor-specific mutated segment of EGFRvIII (PEP-3) conjugated to keyhole limpet hemocyanin [KLH (PEP-3-KLH)]...
  8. ncbi request reprint Biphasic malignant meningioma: a comparative genomic hybridization study
    A B Heimberger
    Department of Neurosurgery, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Neuropathol 21:258-64. 2002
    ..Furthermore, CGH showed that the histologically appearing low-grade fibroblastic component had not solely the characteristic alterations of a benign meningioma but had already progressed to an atypical meningioma...
  9. pmc Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?
    Amy B Heimberger
    Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Unit 442, FC7 3021, Houston, TX 77030 4009, USA
    Neuro Oncol 13:3-13. 2011
    ....
  10. pmc Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study
    Amy B Heimberger
    Department of Neurosurgery, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Neuro Oncol 10:98-103. 2008
    ..In fact, the temozolomide-induced lymphopenia may prove to be synergistic with a peptide vaccine secondary to inhibition of regulatory T cells or their delayed recovery...
  11. pmc Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
    John H Sampson
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 28:4722-9. 2010
    ..Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms...
  12. pmc Clinical applications of a peptide-based vaccine for glioblastoma
    Charles W Kanaly
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Box 3050, 220 Sands Building, Research Drive, Durham, NC 27710, USA
    Neurosurg Clin N Am 21:95-109. 2010
    ....
  13. pmc Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model
    Ling Yuan Kong
    Department of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 16:2550-61. 2010
    ..We hypothesized that WP1193, a novel inhibitor of STAT3 signaling, would enhance the antitumor activity of IFN-alpha against metastatic melanoma...
  14. doi request reprint Topotecan enhances immune clearance of gliomas
    Jun Wei
    Department of Neurosurgery, Unit 442, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Cancer Immunol Immunother 58:259-70. 2009
    ..Based on our data we conclude that drugs, such as topotecan, which cause up regulation of Fas on glioma cells can be potentially exploited with immunotherapy to enhance immune clearance of tumors via Fas signaling...
  15. ncbi request reprint Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma
    Amy B Heimberger
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Neurosurgery 50:158-64; discussion 164-6. 2002
    ..The purpose of this study was to demonstrate that DC-based immunizations directed solely against this tumor-specific antigen, which is commonly found on tumors that originate within or metastasize to the brain, could be efficacious...
  16. ncbi request reprint Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy
    Justin T Jordan
    Department of Neurosurgery, Unit 442, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    Cancer Immunol Immunother 57:123-31. 2008
    ....
  17. pmc EGFRvIII-targeted vaccination therapy of malignant glioma
    Bryan D Choi
    Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Brain Pathol 19:713-23. 2009
    ..Additionally, the corresponding therapeutic outcomes observed in these studies lend credence to the potential role of peptide-based vaccination strategies among emerging antitumor immunotherapies in patients with malignant glioma...
  18. pmc Glioma-associated cancer-initiating cells induce immunosuppression
    Jun Wei
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 16:461-73. 2010
    ....
  19. ncbi request reprint Immunotherapy for human glioma: innovative approaches and recent results
    S Farzana Hussain
    University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    Expert Rev Anticancer Ther 5:777-90. 2005
    ..This review will provide an overview of the juxtaposition of the immune system and CNS, and will discuss the most recent and ongoing immunotherapeutic clinical trials that are demonstrating promising results...
  20. pmc Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Semin Immunol 20:267-75. 2008
    ..The recurrence of EGFRvIII-negative tumors in our patients, however, highlights the need for targeting a broader repertoire of tumor-specific antigens...
  21. pmc An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Mol Cancer Ther 8:2773-9. 2009
    ..7 months (C.I.(95), 14.5-25.6). Overall median survival from time of histologic diagnosis was 22.8 months (C.I.(95), 17.5-29). This study establishes the EGFRvIII mutation as a safe and immunogenic tumor-specific target for immunotherapy...
  22. ncbi request reprint Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target
    Julia A Barnett
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:3559-67. 2007
    ..To evaluate the viability of further research efforts targeting this antigen, we examined the expression of CYP1B1 in glial cell malignancies...
  23. pmc A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells
    Ling Yuan Kong
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:5759-68. 2008
    ..We hypothesized that WP1066, a novel STAT3 blockade agent, has marked antitumor activity, even against the melanoma metastasis to brain, a site typically refractory to therapies...
  24. pmc Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway
    Jun Wei
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Mol Cancer Ther 9:67-78. 2010
    ..These findings indicate that cancer-initiating cells contribute to the immune evasion of GBM and that blockade of the STAT3 pathway has therapeutic potential...
  25. pmc The role of tregs in glioma-mediated immunosuppression: potential target for intervention
    William Humphries
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Neurosurg Clin N Am 21:125-37. 2010
    ....
  26. ncbi request reprint Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa)
    Amy B Heimberger
    Department of Surgery, Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 8:3496-502. 2002
    ..On the basis of these observations, we believe that clinical trials of ZD1839 against brain tumors expressing EGFR are warranted, but that special consideration should be given to tumors that coexpress EGFRvIII...
  27. pmc The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses
    S Farzana Hussain
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, P O Box 301402, Houston, TX 77230 1402, USA
    Neuro Oncol 8:261-79. 2006
    ..Furthermore, the presence of regulatory T cells may also contribute to the lack of effective immune activation against malignant human gliomas...
  28. ncbi request reprint Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma
    Christopher E Pelloski
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 12:3935-41. 2006
    ..This study was conducted to determine whether any of these markers are associated with survival time and response to radiation in glioblastoma...
  29. ncbi request reprint A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients
    S Farzana Hussain
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 67:9630-6. 2007
    ....
  30. pmc The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas
    Mohamed Abou-Ghazal
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:8228-35. 2008
    ....
  31. pmc A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells
    Ling Yuan Kong
    Department of Neurosurgery, Unit 442, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Cancer Immunol Immunother 58:1023-32. 2009
    ..These results suggest that WP1066 enhances T cell cytotoxicity against melanoma through inhibition of Tregs...
  32. ncbi request reprint Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma
    Christopher E Pelloski
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:2288-94. 2007
    ..We sought to evaluate the clinical significance of GBM subtypes as defined by EGFRvIII status...
  33. pmc Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Neuro Oncol 13:324-33. 2011
    ..EGFRvIII-targeted vaccination induces patient immune responses despite therapeutic TMZ-induced lymphopenia and eliminates EGFRvIII-expressing tumor cells without autoimmunity...
  34. doi request reprint Awake craniotomy for brain tumors near eloquent cortex: correlation of intraoperative cortical mapping with neurological outcomes in 309 consecutive patients
    Stefan S Kim
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Neurosurgery 64:836-45; discussion 345-6. 2009
    ..We report herein the results of a retrospective study of cortical mapping and subsequent clinical outcomes in a large series of patients...
  35. ncbi request reprint Central nervous system cancers: Clinical Practice Guidelines in Oncology
    Steven S Brem
    J Natl Compr Canc Netw 3:644-90. 2005
  36. pmc Altered adenosine-to-inosine RNA editing in human cancer
    Nurit Paz
    Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel
    Genome Res 17:1586-95. 2007
    ..Altered epigenetic control was recently shown to play a central role in oncogenesis. We suggest that A-to-I RNA editing may serve as an additional epigenetic mechanism relevant to cancer development and progression...

Research Grants4

  1. Modulation of Microglia and T Cell Interactions in Malignant Glioma
    Amy Heimberger; Fiscal Year: 2007
    ..By further delineating the mechanisms underlying the failure of the immune system to eradicate or suppress gliomas, we hope to improve the efficacy of future immunotherapy, increase longevity and quality of life of glioma patients. ..
  2. Modulation of Microglia and T Cell Interactions in Malignant Glioma
    Amy Heimberger; Fiscal Year: 2009
    ..By further delineating the mechanisms underlying the failure of the immune system to eradicate or suppress gliomas, we hope to improve the efficacy of future immunotherapy, increase longevity and quality of life of glioma patients. ..
  3. Modulation of Microglia and T Cell Interactions in Malignant Glioma
    AMY BETH HEIMBERGER; Fiscal Year: 2010
    ..By further delineating the mechanisms underlying the failure of the immune system to eradicate or suppress gliomas, we hope to improve the efficacy of future immunotherapy, increase longevity and quality of life of glioma patients. ..